CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Deferasirox

地拉罗司 杂质对照品Deferasirox Impurities

40 个杂质条目40 impurity entries

本页汇总 地拉罗司 的 40 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 40 impurity reference standards of Deferasirox. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 地拉罗司(Deferasirox)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and Validation of Robust, Highly Sensitive and Stability-Indicating RP-HPLC Method for Estimation of Deferasirox and its Degradation Products
    Journal of chromatographic science · 2024 · Shishodia T et al.  ·  PMID 37070383  ·  DOI
  2. 杂质研究Impurity studiesIdentification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS
    Journal of pharmaceutical and biomedical analysis · 2012 · Thomas S et al.  ·  PMID 22361658  ·  DOI
  3. 杂质研究Impurity studiesSigns of deferasirox genotoxicity
    Cytotechnology · 2014 · Ila HB et al.  ·  PMID 23887830  ·  DOI
  4. 分析方法Analytical MethodsA simple LC-MS/MS method for determination of deferasirox in human plasma: Troubleshooting of interference from ferric ion in method development and its application
    Journal of pharmaceutical and biomedical analysis · 2018 · Li T et al.  ·  PMID 29328981  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of deuterium-labelled isotopomer of deferasirox
    Journal of labelled compounds & radiopharmaceuticals · 2015 · Havaldar FH et al.  ·  PMID 25693166  ·  DOI

地拉罗司 —— 原料药与杂质对照品Deferasirox — drug substance & impurities

共 41 个条目(含原料药本体)41 items incl. the drug substance
Deferasirox structure
原料药 APIAPI
地拉罗司Deferasirox
Deferasirox
CAS No.201530-41-8
Chemical FormulaC21H15N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 1 structure
1
地拉罗司杂质1Deferasirox Impurity 1
Deferasirox Impurity 1
CAS No.619-67-0
Chemical FormulaC7H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 5 structure
5
地拉罗司杂质5Deferasirox Impurity 5
Deferasirox Impurity 5
CAS No.5326-27-2
Chemical FormulaC7H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 6 structure
6
地拉罗司杂质6Deferasirox Impurity 6
Deferasirox Impurity 6
CAS No.1972-71-0
Chemical FormulaC14H11NO4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 7 structure
7
地拉罗司杂质7Deferasirox Impurity 7
Deferasirox Impurity 7
CAS No.1266741-05-2
Chemical FormulaC22H17N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 8 structure
8
地拉罗司杂质8Deferasirox Impurity 8
Deferasirox Impurity 8
CAS No.201530-79-2
Chemical FormulaC23H19N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 10 structure
10
地拉罗司杂质10Deferasirox Impurity 10
Deferasirox Impurity 10
CAS No.1266741-29-0
Chemical FormulaC24H21N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 11 structure
11
地拉罗司杂质11Deferasirox Impurity 11
Deferasirox Impurity 11
CAS No.201530-78-1
Chemical FormulaC21H15N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 12 structure
12
地拉罗司杂质12Deferasirox Impurity 12
Deferasirox Impurity 12
CAS No.14685-90-6
Chemical FormulaC9H12N2O2
Purity>95%现货In stock
10mg25mg50mg100mg
Deferasirox Impurity 14 structure
14
地拉罗司杂质14Deferasirox Impurity 14
Deferasirox Impurity 14
CAS No.68917-75-9
Chemical FormulaC8H8O3
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 15 structure
15
地拉罗司杂质15Deferasirox Impurity 15
Deferasirox Impurity 15
CAS No.1395346-28-7
Chemical FormulaC28H19N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 16 structure
16
地拉罗司杂质16Deferasirox Impurity 16
Deferasirox Impurity 16
CAS No.1395346-29-8
Chemical FormulaC23H17N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 17 structure
17
地拉罗司杂质17Deferasirox Impurity 17
Deferasirox Impurity 17
CAS No.63874-38-4
Chemical FormulaC9H9NO4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 18 structure
18
地拉罗司杂质18Deferasirox Impurity 18
Deferasirox Impurity 18
CAS No.1218-69-5
Chemical FormulaC14H9NO3
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 19 structure
19
地拉罗司杂质19Deferasirox Impurity 19
Deferasirox Impurity 19
CAS No.65-45-2
Chemical FormulaC7H7NO2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 20 structure
20
地拉罗司杂质20Deferasirox Impurity 20
Deferasirox Impurity 20
CAS No.82019-50-9
Chemical FormulaC7H4F3NO
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 21 structure
21
地拉罗司杂质21Deferasirox Impurity 21
Deferasirox Impurity 21
CAS No.524746-12-1
Chemical FormulaC21H15N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 23 structure
23
地拉罗司杂质23Deferasirox Impurity 23
Deferasirox Impurity 23
CAS No.2254105-61-6
Chemical FormulaC21H15N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 25 structure
25
地拉罗司杂质25Deferasirox Impurity 25
Deferasirox Impurity 25
CAS No.619-05-6
Chemical FormulaC7H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 26 structure
26
地拉罗司杂质26Deferasirox Impurity 26
Deferasirox Impurity 26
CAS No.51-44-5
Chemical FormulaC7H4Cl2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 27 structure
27
地拉罗司杂质27Deferasirox Impurity 27
Deferasirox Impurity 27
CAS No.528-45-0
Chemical FormulaC7H4N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 28 structure
28
地拉罗司杂质28Deferasirox Impurity 28
Deferasirox Impurity 28
CAS No.535-87-5
Chemical FormulaC7H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 29 structure
29
地拉罗司杂质29Deferasirox Impurity 29
Deferasirox Impurity 29
CAS No.51-36-5
Chemical FormulaC7H4Cl2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 30 structure
30
地拉罗司杂质30Deferasirox Impurity 30
Deferasirox Impurity 30
CAS No.2905-67-1
Chemical FormulaC8H6Cl2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 31 structure
31
地拉罗司杂质31Deferasirox Impurity 31
Deferasirox Impurity 31
CAS No.110964-79-9
Chemical FormulaC8H7NO6S
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 32 structure
32
地拉罗司杂质32Deferasirox Impurity 32
Deferasirox Impurity 32
CAS No.93-98-1
Chemical FormulaC13H11NO
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 33 structure
33
地拉罗司杂质33Deferasirox Impurity 33
Deferasirox Impurity 33
CAS No.14178-42-8
Chemical FormulaC12H10N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 35 structure
35
地拉罗司杂质35Deferasirox Impurity 35
Deferasirox Impurity 35
CAS No.99-34-3
Chemical FormulaC7H4N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 36 structure
36
地拉罗司杂质36Deferasirox Impurity 36
Deferasirox Impurity 36
CAS No.2702-58-1
Chemical FormulaC8H6N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 37 structure
37
地拉罗司杂质37Deferasirox Impurity 37
Deferasirox Impurity 37
CAS No.79540-50-4
Chemical FormulaC16H15Cl2NO3
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 38 structure
38
地拉罗司杂质38Deferasirox Impurity 38
Deferasirox Impurity 38
CAS No.1688656-86-1
Chemical FormulaC28H16N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 40 structure
40
地拉罗司杂质40Deferasirox Impurity 40
Deferasirox Impurity 40
CAS No.2732310-58-4
Chemical FormulaC21H13NO5
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 41 structure
41
地拉罗司杂质41Deferasirox Impurity 41
Deferasirox Impurity 41
CAS No.38235-71-1
Chemical FormulaC7H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 44 structure
44
地拉罗司杂质44Deferasirox Impurity 44
Deferasirox Impurity 44
CAS No.108129-45-9
Chemical FormulaC8H8N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 45 structure
45
地拉罗司杂质45Deferasirox Impurity 45
Deferasirox Impurity 45
CAS No.89366-34-7
Chemical FormulaC9H9NO4
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 46 structure
46
地拉罗司杂质46Deferasirox Impurity 46
Deferasirox Impurity 46
CAS No.938-73-8
Chemical FormulaC9H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 47 structure
47
地拉罗司杂质47Deferasirox Impurity 47
Deferasirox Impurity 47
CAS No.1233196-92-3
Chemical FormulaC27H23N3O10
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 48 structure
48
地拉罗司杂质48Deferasirox Impurity 48
Deferasirox Impurity 48
CAS No.37901-95-4
Chemical FormulaC8H10N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 49 structure
49
地拉罗司杂质49Deferasirox Impurity 49
Deferasirox Impurity 49
CAS No.4510-12-7
Chemical FormulaC8H10N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 51 structure
51
地拉罗司杂质51Deferasirox Impurity 51
Deferasirox Impurity 51
CAS No.1688656-83-8
Chemical FormulaC42H28N6O8S
Purity>95%询价On request
10mg25mg50mg100mg
Deferasirox Impurity 52 structure
52
地拉罗司杂质52Deferasirox Impurity 52
Deferasirox Impurity 52
CAS No.1688656-84-9
Chemical FormulaC42H28N6O9S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

地拉罗司 —— 研究文献与合成路线Deferasirox — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 地拉罗司 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Deferasirox. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Development and Validation of Robust, Highly Sensitive and Stability-Indicating RP-HPLC Method for Estimation of Deferasirox and its Degradation Products
    Shishodia T, Grover P, Nagarajan K, et al. · Journal of chromatographic science · 2024
  2. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS
    Thomas S, Chandra Joshi S, Vir D, et al. · Journal of pharmaceutical and biomedical analysis · 2012 · 被引 9cited 9
  3. Terbium-sensitized fluorescence method for the determination of deferasirox in biological fluids and tablet formulation
    Manzoori JL, Jouyban A, Amjadi M, et al. · Luminescence : the journal of biological and chemical luminescence · 2011 · 被引 15cited 15
  4. Spectrofluorimetric determination of buparvaquone in biological fluids, food samples and a pharmaceutical formulation by using terbium-deferasirox probe
    Manzoori JL, Jouyban A, Amjadi M, et al. · Food chemistry · 2011 · 被引 7cited 7

合成与制备工艺专利Synthesis & process patents

  1. PROCESSES FOR THE PREPARATION OF DEFERASIROX, AND DEFERASIROX POLYMORPHS
    MIZHIRITSKII MICHAEL, MAROM EHUD, RUBNOV SHAI · 公开号 WO2011070560WO2011070560 · 2011
  2. SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF
    PATIL RAJENDRA SURYABHAN, CHARUGUNDLA KISHORE, NEELA PRAVEEN KUMAR, PRADHAN NITIN SHARADCHANDRA, et al. · 公开号 US2011171138US2011171138 · 2011
  3. SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF
    PATIL RAJENDRA SURYABHAN, CHARUGUNDLA KISHORE, NEELA PRAVEEN KUMAR, PRADHAN NITIN SHARADCHANDRA, et al. · 公开号 WO2009147529WO2009147529 · 2009
  4. SOLID STATE FORMS OF DEFERASIROX SALTS AND PROCESS FOR THE PREPARATION THEREOF
    NEELA PRAVEEN KUMAR, CHARUGUNDLA KISHORE, PATIL RAJENDRA SURYABHAN, PRADHAN NITIN SHARADCHANDRA, et al. · 公开号 US2011097413US2011097413 · 2011
  5. SOLID STATE FORMS OF DEFERASIROX SALTS AND PROCESS FOR THE PREPARATION THEREOF
    NEELA PRAVEEN KUMAR, CHARUGUNDLA KISHORE, PATIL RAJENDRA SURYABHAN, PRADHAN NITIN SHARADCHANDRA, et al. · 公开号 EP2291360EP2291360 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

地拉罗司 杂质谱研究要点Deferasirox — impurity profiling notes

下面这些是拿到 地拉罗司 的 41 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 41 impurity entries for Deferasirox, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances